Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

View Now

EU Orphan Drug Designation – overcoming regulatory challenges

View Now

Preparing for the New Era of Hybrid Regulatory Inspections

The FDA has strengthened its use of remote inspection and integrate desk-based assessments with traditional on-site visits. This outlines what you need to know about this new era of hybrid inspections

Learn More

See Parexel's latest COVID-19 expert content

View all

8 things you need to know about eCTDs in China

Although eCTDs are a huge step forward for standardization in the Asia Pacific, there are several important things you need to know before you submit your dossier electronically.

View Now

Error - something went wrong!

Speak to one of our experts today

We'll be in touch shortly!

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

While COVID-19 disrupted business operations, the importance of data integrity in manufacturing has not diminished. How can sponsors reconcile the adaptations they made during the emergency?

Learn More

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

David Brown, Global Head of Epidemiology, summarizes the three FDA guidances related to data sources, data standards, and regulatory considerations in RWE/RWD and benefits of early engagement.

Learn More

How to better prepare patients for a cell or gene therapy trial

Parexel spoke with Doug Olson, Cancer survivor and CAR T-cell patient, about how healthcare providers and trial sponsors can better communicate with patients about CGTs.

View Now

Meet our experts

Read their bios

Overview of China's Market Approval Policy Med Insurance Payment System

View Now

Communicating Value to Providers and Payers

View Now

Early planning can help you make the most of expedited regulatory pathways

View Now

How biotechs can strengthen their value story with advanced analytics

Read five ways biotech companies can enhance their value story with advanced analytics.

View Now

Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

For payment systems to evolve to deal with reimbursement and market access challenges, payers are taking a new look at evidence generation and data usage. Read how pragmatic trials can help >

Learn More

New endpoints for early-stage cancer are gaining regulatory traction

View Now

Five lessons for building an external control arm that regulators can use

View Now

How emerging biotechs can enter the Chinese market and prosper

In this article, Parexel experts outline five approaches that foreign companies with limited resources should use to gain a foothold in the Chinese market.

View Now

Making Expedited Regulatory Pathways Work for Global Drug Development Programs

Article from December 2021 edition of Applied Clinical Trials. Parexel regulatory experts offer top tips for working with regulators on a global scale.

View Now

Three strategies for articulating a coherent product value story

Articulating a coherent product value story from the start of development can help companies attract investors.

View Now

Biosimilar Development: Are therapeutic clinical trials needed?

In this article, Regulatory expert, Cecil Nick, looks at the latest MHRA guidance and what the future holds for biosimilar development.

Learn More

Expedited Pathways Comparisons - US EU CHN

Slides presented during virtual roundtable, entitled "Making expedited regulatory pathways work for global drug development programs"

View Now

What to know about FDA INTERACT meetings

Our regulatory expert and former FDA regulator Steve Winitsky shares his advice on planning and preparing for an effective INTERACT meeting.

View Now

Regulatory & Access Resources

Latest Content

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

EU Orphan Drug Designation – overcoming regulatory challenges

Preparing for the New Era of Hybrid Regulatory Inspections

8 things you need to know about eCTDs in China

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

How to better prepare patients for a cell or gene therapy trial

Overview of China's Market Approval Policy Med Insurance Payment System

Communicating Value to Providers and Payers

Early planning can help you make the most of expedited regulatory pathways

How biotechs can strengthen their value story with advanced analytics

Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

New endpoints for early-stage cancer are gaining regulatory traction

Five lessons for building an external control arm that regulators can use

How emerging biotechs can enter the Chinese market and prosper

Making Expedited Regulatory Pathways Work for Global Drug Development Programs

Three strategies for articulating a coherent product value story

Biosimilar Development: Are therapeutic clinical trials needed?

Expedited Pathways Comparisons - US EU CHN

What to know about FDA INTERACT meetings